Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE) (ELEVATE-LTE)

26. juni 2026 opdateret af: Entrada Therapeutics, Inc.

A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

This is a study of investigational medicines ENTR-601-44 and ENTR-601-45 designed to evaluate the long-term safety and tolerability of study drugs in participants with Duchenne muscular dystrophy (DMD).

The investigational medicines are currently being investigated in multiple ascending dose parent studies. After participants complete their respective parent study, there is a need to understand the effects of long-term administration of ENTR-601-44 and ENTR-601-45.

Participants enrolling in this study will begin this long-term extension (LTE) study at the dose level they received upon completion of the parent study with possible dose escalation in the LTE study based on emerging safety and efficacy data from the parent studies.

Participants will:

  • Receive study treatment in the form of multiple intravenous (IV) infusions (slow injections) into a vein over the course of several weeks
  • Visit the clinic regularly for checkups and tests such as: blood and urine tests, physical examinations, questionnaires, and excersice tests. Participants will have a muscle biopsy at the beginning of their participation and after their last dose to allow researchers to compare whether there have been changes in the muscle as a results of the study drug.

Participants are allowed to continue receiving their standard of care therapy for DMD during the study, as long as their health remains stable.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

80

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Belgien
      • Ghent, Belgien, 9000
        • University Hospital Gent
      • Leuven, Belgien, 3000
        • UZ Leuven
      • Liège, Belgien, 4000
        • Centre Hospitalier Regional de la Citadelle
  • Det Forenede Kongerige
      • Leeds, Det Forenede Kongerige, LS1 3EX
        • Leeds General Infirmary
      • Liverpool, Det Forenede Kongerige, L122AP
        • Alder Hey Children's NHS Foundation Trust
      • London, Det Forenede Kongerige, WC1N 3JH
        • Great Ormond Street Hospital for Children
      • Manchester, Det Forenede Kongerige, M13 9WL
        • Royal Manchester Children's Hospital
      • Newcastle upon Tyne, Det Forenede Kongerige, NE1 3BZ
        • Freeman Hospital
      • Oxford, Det Forenede Kongerige, OX3 9DU
        • Oxford University Hospitals NHS Foundation Trust
  • Holland
      • Leiden, Holland, 2333 ZA
        • Leids Universitair Medisch Centrum
      • Nijmegen, Holland, 6525 GA
        • Stichting Radboud Universitair Medisch Centrum
  • Italien
      • Milan, Italien, 20132
        • IRCCS Ospedale San Raffaele
      • Milan, Italien, 20162
        • Fondazione Serena Onlus - Centro Clinico NeMO Milano
      • Roma, Italien, 00168
        • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
      • Rome, Italien, 00165
        • Ospedale Pediatrico Bambino Gesù
  • Spanien
      • Barcelona, Spanien, 08035
        • Hospital Universitario Vall d'Hebron
      • Barcelona, Spanien, 08950
        • Hospital Sant Joan De Deu

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Willing and able to provide consent (if at age of majority) or assent (if a minor)
  • Participant completed clinical study ENTR-601-44-201 or ENTR-601-45-201
  • Males who are sexually active with a female partner of childbearing potential must agree to use condoms during sexual intercourse

Exclusion Criteria:

  • Any change from the applicable parent study eligibility criteria, including safety events during the parent study, that in the opinion of the investigator in consultation with the medical monitor and/or sponsor designee precludes safe use of study drug
  • Participant has a condition or circumstance that in the view of the investigator places the subject at high risk of poor treatment compliance or for not completing the study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: ENTR-601-44
ENTR-601-44 intravenous infusion every 6 weeks
Medicin: ENTR-601-44
ENTR-601-44 intravenous infusion
Eksperimentel: ENTR-601-45
ENTR-601-45 intravenous infusion every 6 weeks
Medicin: ENTR-601-45
ENTR-601-45 intravenous infusion

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and OL Period)
Tidsramme: From baseline through End of Study (up to 2 years).
Safety will be assessed by monitoring adverse events, physical examination, vital signs and clinical laboratory tests.
From baseline through End of Study (up to 2 years).

Sekundære resultatmål

Resultatmål
Tidsramme
Plasma concentration of study drug compounds and their final metabolite
Tidsramme: From baseline through End of Study (up to 2 years).
From baseline through End of Study (up to 2 years).
Change from parent study Part A and OL Period baselines to LTE EOS in 10-Meter Walk/Run (10MWR)
Tidsramme: From baseline through End of Study (up to 2 years).
From baseline through End of Study (up to 2 years).
Change from parent study Part A and OL Period baselines to LTE EOS in timed rise from floor (TRF)
Tidsramme: From baseline through End of Study (up to 2 years).
From baseline through End of Study (up to 2 years).
Change from parent study Part A and OL Period baselines to LTE EOS in Timed 4-Stair Climb (4SC)
Tidsramme: From baseline through End of Study (up to 2 years).
From baseline through End of Study (up to 2 years).
Change from parent study Part A and OL Period baselines to LTE EOS in stride velocity 95th centile (SV95C)
Tidsramme: From baseline through End of Study (up to 2 years).
From baseline through End of Study (up to 2 years).
Change from parent study Part A and OL Period baselines to LTE EOS in North Star Ambulatory Assessment (NSAA)
Tidsramme: From baseline through End of Study (up to 2 years).
From baseline through End of Study (up to 2 years).
Change from parent study Part A and OL Period baselines to LTE EOS in Performance of the Upper Limb v2.0 (PUL 2.0)
Tidsramme: From baseline through End of Study (up to 2 years).
From baseline through End of Study (up to 2 years).
Anti-drug antibody (ADA) and anti-dystrophin antibody in serum
Tidsramme: From baseline through End of Study (up to 2 years).
From baseline through End of Study (up to 2 years).

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Entrada Therapeutics, Inc.

Efterforskere

  • Studieleder: Entrada Therapeutics Clinical Trials, Entrada Therapeutics, Inc.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. august 2026

Primær færdiggørelse (Anslået)

1. marts 2032

Studieafslutning (Anslået)

1. marts 2032

Datoer for studieregistrering

Først indsendt

11. juni 2026

Først indsendt, der opfyldte QC-kriterier

26. juni 2026

Først opslået (Faktiske)

2. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

2. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

26. juni 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • ENTR-601-DMD-202
  • 2025-525124-10-00 (Ctis)
  • U1111-1334-9287 (Anden identifikator: WHO)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

The datasets generated during and/or analyzed during the current study are not expected to be made available due to the data´s high commercial sensitivity.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med ENTR-601-44

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Brazil

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner